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OBJECTIVE — To compare the safety and efﬁcacy of insulin analogs and human insulins
both during acute intravenous treatment and during the transition to subcutaneous insulin in
patients with diabetic ketoacidosis (DKA).
RESEARCH DESIGN AND METHODS — In a controlled multicenter and open-label
trial, we randomly assigned patients with DKA to receive intravenous treatment with regular or
glulisine insulin until resolution of DKA. After resolution of ketoacidosis, patients treated with
intravenous regular insulin were transitioned to subcutaneous NPH and regular insulin twice
daily (n  34). Patients treated with intravenous glulisine insulin were transitioned to subcuta-
neous glargine once daily and glulisine before meals (n  34).
RESULTS — Therewerenodifferencesinthemeandurationoftreatmentorintheamountof
insulin infusion until resolution of DKA between intravenous treatment with regular and glu-
lisine insulin. After transition to subcutaneous insulin, there were no differences in mean daily
blood glucose levels, but patients treated with NPH and regular insulin had a higher rate of
hypoglycemia (blood glucose 70 mg/dl). Fourteen patients (41%) treated with NPH and
regular insulin had 26 episodes of hypoglycemia and 5 patients (15%) in the glargine and
glulisine group had 8 episodes of hypoglycemia (P  0.03).
CONCLUSIONS — Regularandglulisineinsulinareequallyeffectiveduringtheacutetreat-
ment of DKA. A transition to subcutaneous glargine and glulisine after resolution of DKA
resulted in similar glycemic control but in a lower rate of hypoglycemia than with NPH and
regular insulin. Thus, a basal bolus regimen with glargine and glulisine is safer and should be
preferred over NPH and regular insulin after the resolution of DKA.
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D
iabetic ketoacidosis (DKA) is the
most serious hyperglycemic emer-
gency in patients with type 1 and
type2diabetes.DKAisthemostcommon
causeofdeathinchildrenandadolescents
with type 1 diabetes and accounts for half
ofalldeathsindiabeticpatientsaged24
years (1). Recent series in adult patients
with DKA have reported a mortality rate
of 5% (2,3). DKA is responsible for
100,000hospitaladmissionsintheU.S.
and substantial spending related to direct
and indirect costs (2). It has been esti-
mated that treatment of DKA episodes
represent more than one of every four
health care dollars spent on direct medi-
cal care for adult patients with type 1 di-
abetes (4).
ThemainstayinthetreatmentofDKA
involves the administration of regular in-
sulin via continuous intravenous infusion
orbyfrequentsubcutaneousorintramus-
cular injections of regular insulin or
rapid-acting insulin analogs (5–7). Al-
though several controlled studies have
shown that low-dose insulin therapy is
effective regardless of the route of admin-
istration, most patients are treated with
intravenous regular insulin until resolu-
tion of DKA (8). When this occurs, sub-
cutaneous insulin therapy can be started.
The American Diabetes Association rec-
ommends the transition to NPH and reg-
ular insulin twice daily or to a multidose
regimen of short- or rapid-acting and in-
termediate- or long-acting insulins (2,8).
Several studies have reported hospital
rates of hypoglycemic events up to 37%
with the use of NPH and regular insulin
after discontinuation of intravenous insu-
lin (3,9). The inadequate duration of ac-
tion of NPH insulin and an undesirable
peak activity at 4–6 h after injection (10)
as well as the high day-to-day variability
in absorption (11) partially explains the
high rate of hypoglycemic events. In re-
cent years, the use of long-acting basal
and rapid-acting insulin analogs has been
recommended as a more physiological
approach than NPH and regular insulin
for glucose control in the hospital
(12,13); however, no previous studies
have evaluated the safety and efﬁcacy of
insulin analogs in the management of
patients with hyperglycemic crises. Ac-
cordingly, the aim of this multicenter,
randomized, open-label study was 1)t o
determine differences in treatment re-
sponse between regular insulin and rap-
id-acting insulin analogs during the acute
intravenous treatment of DKA and 2)t o
determine differences between treatment
with glargine plus glulisine and a split-
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lin after the transition to subcutaneous
insulin following resolution of DKA.
RESEARCH DESIGN AND
METHODS— A total of 74 patients
with DKA were randomly assigned in this
study. Of them, six patients were ex-
cluded because four withdrew consent
before or shortly after initiation of insulin
therapy, one patient received glargine in-
sulin before resolution of DKA, and one
patient was treated with intravenous as-
partinsulininsteadofregularinsulin.The
remaining 68 patients served as the study
population.ThediagnosisofDKAwases-
tablished by standard criteria (8). We ex-
cluded patients with systolic blood
pressure 90 mmHg after the adminis-
tration of1lo fnormal saline, patients in
a comatose state, and patients with acute
myocardial ischemia, congestive heart
failure, end-stage renal or hepatic failure,
dementia, and pregnancy. This study was
conducted at Grady Memorial Hospital,
Atlanta, Georgia, and at Hennepin
County Medical Center, Minneapolis,
Minnesota, and was approved by dual in-
stitutional review boards.
Patients with DKA were randomly as-
signed in the emergency department to
receivetreatmentwithregular(n34)or
glulisine (n  34) insulin intravenously
until resolution of DKA. After resolution
of DKA, patients treated with intravenous
regular insulin were transitioned to re-
ceive subcutaneous NPH and regular in-
sulin twice daily. Patients treated with
intravenous glulisine insulin were transi-
tionedtoglargineoncedailyandglulisine
before meals.
Treatment protocols
Patients were managed by members of
the internal medicine residency pro-
grams of the respective institutions,
who received copies of the assigned
treatment protocol (supplementary Ta-
ble A in an online appendix, available at
http://care.diabetesjournals.org/cgi/content/
full/dc09-0169/DC1). Orders for intrave-
nous ﬂuids, potassium, and bicarbonate
administration were similar in both
groups and followed current American
DiabetesAssociationguidelines(2,8).Ini-
tial orders for intravenous regular and
glulisine insulin included an initial bolus
of 0.1 unit/kg, followed by a continuous
intravenous infusion calculated to deliver
0.1 unit   kg
1   h
1 until blood glucose
levels decreased to 250 mg/dl (13.8
mmol/l). At that time, intravenous ﬂuids
were changed to dextrose-containing so-
lutions, and the insulin infusion rate was
decreased to 0.05 unit   kg
1   h
1 to
maintain blood glucose of 200 mg/dl
(11.1 mmol/l) until resolution of DKA.
DKA was considered resolved when
blood glucose was 250 mg/dl, the se-
rum bicarbonate level was 18 mmol/l,
and venous pH was 7.30 (2).
After resolution of DKA, insulin infu-
sion was discontinued 2 h after the ad-
ministration of subcutaneous insulin.
Patients with newly diagnosed diabetes
received an initial total daily dose (TDD)
of insulin of 0.6 unit   kg
1   day
1. Sub-
jects receiving insulin therapy before ad-
mission received the same outpatient
insulin amount, with the TDD switched
to glargine and glulisine or to NPH and
regular insulin on a unit-for-unit basis.
Patients treated with subcutaneous
glargineandglulisinereceived50%ofthe
TDD as glargine and 50% as glulisine in-
sulin.Glarginewasgivenoncedailyatthe
same time of day and glulisine was given
inthreeequallydivideddosesbeforeeach
meal. Glargine was given at the full dose
independently of food intake, but to pre-
vent hypoglycemia, the dose of glulisine
was held if a subject was not able to eat a
given meal. Patients treated with NPH
and regular insulin received two-thirds of
theTDDbeforebreakfastandone-thirdof
the TDD before dinner. The insulin dose
was given as two-thirds NPH and one-
third regular insulin in the morning with
breakfast and two-thirds NPH and one-
third regular insulin in the evening with
dinner.Topreventhypoglycemia,regular
insulin was held if a subject was not able
to eat a given meal; in addition, the dose
of NPH was reduced by 50% if a patient
was kept NPO all day. Insulin dosage was
adjusteddailyaccordingtoglucosevalues
to maintain target blood glucose 140
mg/dl before meals. The insulin dose was
adjusted, and supplemental insulin was
given based on blood glucose levels (sup-
plementaryTableB,availableinanonline
appendix).
The primary outcome of the study
was the determination of differences in
the rate of hypoglycemic events (blood
glucose 70 mg/dl) during the transition
period between treatment groups. Sec-
ondary outcomes included differences in
the time to resolution of DKA and hyper-
glycemia, average blood glucose during
intravenous insulin infusion, mean daily
blood glucose after resolution of DKA,
length of hospital stay, and hospital com-
plications between treatment groups.
Statistical analysis
Based on previous reports, the rate of hy-
poglycemic events (primary end point) in
patients treated with subcutaneous NPH
and regular insulin was estimated to be
37% (3,9). The rate of hypoglycemic
events with basal bolus insulin was esti-
mated to be 10% (14). Using two-sided

2 tests and a type I error of 0.05, we
calculatedthat32patientspergroupwere
needed to have 80% power to detect the
difference in hypoglycemia rate of 30%.
Allowing for 15% loss to follow-up, we
recruited a total of 74 patients with DKA,
ofwhich34patientspergroupcompleted
the study.
All data in the text, tables, and ﬁgures
are means  SD. Two-sample Wilcoxon
tests or Pearson’s 
2 tests were used to
compare patient demographic and clini-
cal characteristics as well as outcomes
measures between treatment groups.
Cross-sectional analyses based on two-
sampleWilcoxontestswereusedtoassess
the group differences in blood glucose
and acid-based parameters during DKA
treatment and mean daily blood glucose
after DKA resolution. In addition, we
used repeated-measures linear models
to examine the group differences while
adjusting for subject’s age, sex, race,
and BMI. P  0.05 was considered sig-
niﬁcant. Statistical analysis was per-
formed using SAS.
RESULTS— The clinical characteris-
tics of study patients on admission are
showninTable1.Themeanage,duration
of diabetes, and precipitating cause for
DKA were similar between treatment
groups.Pooradherencewithinsulinther-
apy was the most common precipitating
causeofDKAandwasrecordedin59%of
patients treated with glulisine and in 79%
of patients in the regular insulin group.
Thelengthofhospitalstaywassimilarbe-
tween patients treated with glargine and
glulisine (2.9  2.2 days) and NPH and
regular insulin (3.3  2.2 days) (NS).
Biochemical parameters on admis-
sion and during treatment were similar in
patients treated with intravenous glu-
lisine and regular insulin (NS). Changes
in blood glucose and acid-base parame-
ters during treatment are shown in Fig. 1.
As suggested by the repeated-measures
analyses, the rate of decline of blood glu-
cose concentration and changes in acid
base parameters during treatment were
not signiﬁcantly different between treat-
mentgroupswithadjustmentforage,sex,
race,andBMI(NS).Themeandurationof
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was not statistically different between
those treated with glulisine (8.9  4.7 h)
and regular insulin (10.5  6.3 h) (NS).
AtresolutionofDKA,themeanbloodglu-
cose concentration and acid-base param-
eters in patients treated with glulisine
insulin (glucose 153  61 mg/dl, bicar-
bonate 20  3 mmol/l, pH 7.33  0.04,
andaniongap8.32.1mEq/l)weresim-
ilar to those in patients treated with intra-
venous regular insulin (glucose 185  58
mg/dl, bicarbonate 19.5  3.7 mEq/l, pH
7.320.04,andaniongap93mEq/l).
During the insulin infusion, six patients
treated with glulisine and four patients
treated with regular insulin developed
oneortwoepisodesofbloodglucose70
mg/dl,butnoneofthemwere40mg/dl.
The amount of insulin administered until
resolution of DKA (70  33 and 76  46
units) and the mean total duration of in-
sulin infusion (15.7  4.5 and 20.5 
12h)werenotdifferentbetweenglulisine
and regular insulin, respectively (NS).
There was no mortality, and none of the
patients had a recurrence of DKA during
their hospital stay.
Aftertransitiontosubcutaneousinsu-
lin therapy, cross-sectional analyses
based on two-sample Wilcoxon tests
showed that there were no signiﬁcant dif-
ferences in the mean daily glucose con-
centration between treatment groups.
However, ﬁtting of a repeated-measures
linear model with or without adjustment
for age, sex, race, and BMI indicated a
Table 1—Patient characteristics on admission
Insulin analogs
(glulisine/glargine)
Human insulin
(NPH/regular)
n 34 34
Age (years) 39  12 38  12
Sex (male/female) 22/12 23/11
Race
African American 29 27
Caucasian 4 6
Other 1
BMI (kg/m
2) 29  92 7  7
Precipitating cause of DKA
Poor compliance 20 (59) 27 (79)
New-onset diabetes 6 (18)
Other medical illness 8 (23) 7 (21)
Glucose (mg/dl) 529  173 564  164
Bicarbonate (mEq/l) 12.8  4.5 12.5  5.0
Venous pH 7.2  0.1 7.1  0.2
Anion gap (mEq/l) 22  62 2  6
-Hydroxybutyrate (mmol/l) 8.0  3.4 7.4  3.3
A1C (%) 11.7  2.2 11.7  2.9
Data are means  SD or n (%).
Figure 1—Changes in metabolic proﬁle in patients with DKA treated with intravenous glulisine (E) and regular insulin (F). To convert the values
for glucose from milligrams per deciliter to millimoles per liter, multiply by 0.05551. A: glucose; B: pH; C: bicarbonate; D: anion gap.
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glargine and glulisine group than that in
the NPH and regular insulin group (P 
0.01).
PatientstreatedwithNPHandregular
insulin had a higher rate of hypoglycemic
events than those treated with a basal bo-
lus regimen (Table 2). Fourteen patients
(41%) treated with NPH and regular in-
sulin had 26 episodes of hypoglycemia
and ﬁve patients (15%) in the glargine
and glulisine group had 8 episodes of hy-
poglycemia(P0.01).Threeoftheseep-
isodes in the NPH and regular insulin
group and one in the glargine/glulisine
group were 40 mg/dl. None of the epi-
sodes of hypoglycemia in either group
were associated with loss of conscious-
ness or seizure.
The TDD of subcutaneous insulin
was similar between groups (Table 3).
The mean total daily insulin dose includ-
ing supplemental insulin was 60  30
units in the glargine and glulisine group
and5824unitsintheNPHandregular
insulin group (NS). In addition, there
were no differences in the amount of sup-
plements of insulin glulisine (13  10
units) and regular insulin (12  6 units)
(NS).
CONCLUSIONS— This is the ﬁrst
prospective randomized trial to compare
the use of insulin analogs and human in-
sulins both during acute intravenous
treatment and during the transition to
subcutaneous insulin in patients with
DKA. During the initial treatment phase,
we observed no differences in the mean
duration of treatment or in the amount of
intravenous insulin administration until
resolution of DKA between regular and
glulisine insulin. After resolution of keto-
acidosis, the transition to subcutaneous
glargine and glulisine insulin resulted in
glycemic control similar to that for NPH
and regular insulin; however, treatment
with glargine and glulisine insulin is safer
and is associated with a signiﬁcantly
lower rate of hypoglycemia. A total of 14
patients(41%)treatedwithNPHandreg-
ular insulin and 5 patients (15%) in the
glargine and glulisine group had one or
more episodes of hypoglycemia (P 
0.03).
The comparable response to intrave-
nous glulisine and regular insulin during
the acute resolution of DKA in this study
is in line with previous reports of gener-
ally equal efﬁcacy and in vivo potency of
intravenous rapid-acting insulin analogs
(glulisine, aspart, and lispro) and regular
insulin in animal and human studies
(15,16). Pharmacokinetics and pharma-
codynamic studies comparing the intra-
venous administration of glulisine and
regularinsulinhaveshownasimilaronset
of action within 20 min, a similar distri-
bution and elimination proﬁle, and
equivalent glucose utilization and dis-
posal on a molar, unit-per-unit basis
(16,17).Thepresentstudyconﬁrmsthese
observationsandprovidesevidenceofthe
equal efﬁcacy and in vivo potency of in-
travenous rapid-acting insulin analogs
andregularinsulininpatientswithsevere
hyperglycemia and ketoacidosis. Their
comparableinvivopotencyisattributable
to their similar receptor binding afﬁnity
and receptor-mediated clearance (18).
Our study and these previous reports in-
dicate that treatments with intravenous
glulisine and regular insulin are equally
safeandefﬁcaciousintheacutemanage-
ment of patients with DKA. However,
intravenous regular insulin is more
cost-effective and should be preferred
over rapid-acting insulin analogs dur-
ing the acute intravenous treatment
phase of DKA.
Previous randomized studies in pa-
tients with DKA have focused on the
amount and route of insulin administra-
tion during the acute resolution phase of
ketoacidosis (2,3). Few studies, however,
have focused on the transition period to
subcutaneous insulin after the resolution
of DKA. Accordingly, in this study we
aimed to compare differences between
treatmentwithbasalbolusinsulinanalogs
and NPH and regular insulin after resolu-
tion of DKA. We found no differences in
the daily glucose concentration between
treatment groups; however, patients
treated with NPH and regular insulin had
higher rates of hypoglycemia (41%) than
subjects treated with basal bolus (15%)
insulin (P  0.03). The rate of hypogly-
cemic events in this study is similar to the
rate reported previously with the use of
NPH and regular insulin after discontin-
uation of intravenous therapy (3,9).
The higher rate of hypoglycemia with
human insulins is explained by the phar-
macologicalfeaturesandpeakdurationof
Table 2—Hypoglycemic events during intravenous and subcutaneous insulin treatment
Intravenous insulin therapy Glulisine Regular
Patients with BG 70 mg/dl (%) 4 (12) 6 (18)
Episodes of BG 70 mg/dl 6 7
Patients with BG 40 mg/dl, n (%) 0 (0) 0 (0)
Episodes of BG 40 mg/dl 0 0
Subcutaneous insulin therapy Glargine/glulisine NPH/regular
Patients with BG 70 mg/dl (%) 5 (15) 14 (41)*
Episodes of BG 70 mg/dl 8 26†
Patients with BG 40 mg/dl, n (%) 1 (3) 2 (6)
Episodes of BG 40 mg/dl 1 2
Data are n or n (%). *P  0.03; †P  0.019. BG, blood glucose.
Table 3—Mean blood glucose concentration and daily insulin doses during subcutaneous
insulin treatment after resolution of DKA
Mean daily blood glucose
(mg/dl)
P
Mean daily insulin dose
(units/day)
P
NPH/
regular
Glargine/
glulisine
NPH/
regular
Glargine/
glulisine
Day 1* 188  61 213  76 0.234 50  28 58  33 0.304
Day 2 206  71 220  61 0.370 70  37 73  47 0.877
Day 3 207  86 180  80 0.417 77  45 62  49 0.364
Day 4 211  63 158  44 0.068 70  47 67  50 0.999
Day 5 190  45 124  41 0.068 50  30 47  41 0.302
Data are means  SD. *Day 1  depending on the time of resolution of ketoacidosis and transition to
subcutaneous insulin, a patient could have received one or two doses of NPH/regular insulin or one dose of
glargine and one to three doses of glulisine insulin per day.
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well as the high day-to-day variability in
absorption (11). NPH has an onset of ac-
tion ranging between 2 and 4 h, a peak
concentration of 6–8 h, and a duration
of action up to 20 h (19). Regular human
insulin has an onset of action in 30 min,
peaks at 2–3 h when given subcutane-
ously,andhasadurationofactionof6–8
h (19). The combination of basal and
rapid-acting insulin analogs represents a
more physiological approach to glucose
controlinthehospital.Glargineisapeak-
less, long-acting basal insulin with an on-
set of action of 2 h, a plateau of
biological action at 4–6 h, and duration
of action up to 24 h (20). Glulisine has a
faster onset of action and a shorter dura-
tionofactionaftersubcutaneousinjection
comparedwithregularinsulin(21,22).In
agreement with these results, we recently
reportedthatabasalbolusalgorithmwith
glargine and glulisine is an effective inter-
ventionforglucosecontrolwithalowrate
of hypoglycemic events (3%) in hospital-
ized patients with type 2 diabetes (14).
More recently, we reported that 38% of
hospitalized patients treated with a
combinationofNPHandregularinsulin
experienced one or more episodes of
blood glucose 70 mg/dl during the
hospital stay (23). Minimizing the rate
of hypoglycemia events is of major im-
portance in hospitalized patients be-
cause it may represent an independent
risk factor of poor clinical outcome
(24).
We acknowledge several limitations
in our study, including a relatively small
number of patients and the fact that the
large majority of patients were African
Americans with poor adherence to ther-
apy as the primary precipitating cause of
DKA. We also excluded patients with hy-
povolemic shock, patients in a comatose
state,andpatientswhohadacutemyocar-
dial ischemia, congestive heart failure,
end-stagerenalorhepaticfailure,orpreg-
nancy. A large prospective, randomized
clinical trial of strict glycemic control is
certainly needed to address these impor-
tant issues.
In summary, our study indicates that
intravenous treatments with regular insu-
lin and glulisine insulin are equally effec-
tive with no differences in the mean
duration of treatment or in the amount of
insulin infusion until resolution of DKA.
AfterresolutionofDKA,transitiontosub-
cutaneous glargine once daily and glu-
lisine before meals resulted in similar
glycemic control but in a lower rate of
hypoglycemic events than treatment with
NPH and regular insulin twice daily.
These ﬁndings indicate that a basal bolus
insulin regimen with glargine and glu-
lisineissaferandshouldbepreferredover
NPH and regular insulin after the resolu-
tion of DKA.
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